Pear Therapeutics Announces New CMS HCPCS Code for Prescription Digital Behavioral Therapy Inclusive of All of Its Commercial Products

• CMS establishes new Level II HCPCS code for Prescription Digital Behavioral Therapy, FDA Cleared, per Course of Treatment to describe prescription digital therapeutics (PDTs) including Pear’s PDTs for the treatment of substance use disorder (reSET®), opioid use disorder (reSET-O®), and chronic insomnia (Somryst®), respectively
• The new code marks an important access and reimbursement milestone for providers, payers, patients, and the PDT category, now giving the option for PDTs to be reimbursed through either pharmacy or Durable Medical Equipment (DME) benefits

Excerpt from the Press Release:

BOSTON–(BUSINESS WIRE)–Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today that the Centers for Medicare & Medicaid Services (CMS) established a new Level II Healthcare Common Procedure Coding System (HCPCS) code to describe Prescription Digital Behavioral Therapy, FDA Cleared, per Course of Treatment including prescription digital therapeutics (PDTs) such as Pear’s reSET®, reSET-O® and Somryst®, the only FDA authorized PDTs for the treatment of substance use disorder (SUD), opioid use disorder (OUD) and chronic insomnia, respectively.

The CMS coding decision below was published on February 16, 2022 and the following code for PDTs is scheduled to become effective on April 1, 2022:

Click the button below to read the entire Press Release:

Continue Reading The Press Release